Eli Lilly stock drops 3.01% as oversold signals deepen and resistance holds

Traders Union
All News
Financial News
Eli Lilly slides 3.01% to $959.38

Highlights

Eli Lilly exceeded quarterly forecasts with earnings per share of $7.54 and revenue of $19.29 billion, signaling robust operational performance.
The company is expanding Asian manufacturing, notably boosting supply chain capacity in Japan and China for orforglipron, and saw significant accumulation by Militia Capital Partners LP.
LLY remains under persistent short- and medium-term technical pressure, with weak momentum and sellers dominating, and trades are expected within a $940 to $980 range unless $940 support fails.

Earnings beat and supply chain expansion as selling dominates price action

Eli Lilly reported quarterly earnings on February 4th, posting earnings per share of $7.54 and revenue of $19.29 billion, both surpassing consensus estimates. The company has also increased its investment in supply chain capabilities in Asia, enhancing manufacturing in Japan and expanding capacity in China for the drug orforglipron. Militia Capital Partners LP raised its stake in Eli Lilly by 333.3% in the third quarter, though price action has remained under broader selling pressure.

Oversold signals intensify as weak momentum diverges from price support

Momentum remains weak with a daily MACD showing a clear sell signal and ADX at low levels, suggesting a lack of strong trend direction. Multiple oscillators (RSI at 43.46, Stoch RSI at 24.17, CCI at -87.79) indicate approaching oversold territory, while BBP confirms dominance by sellers. The daily session opened slightly below the previous close ($982.39 vs. $989.12) with no significant gap, and the price is currently near today’s intraday low; the day has seen moderate volatility and downward pressure persists after the open. There is notable divergence between weak short-term momentum and deepening oversold readings, with intraday performance confirming continued seller control.

Further losses likely as resistance limits upside and support is at risk

For the next five trading days, a typical volatility band is expected between $940 and $980, keeping LLY within a sideways to slightly negative corridor. The probability of a price increase is very low (less than 20%), making a further decline much more likely in the short term. The baseline scenario sees the price stabilizing in a narrow range near recent lows; a bullish case requires a move above $1,036.27 resistance, while a bearish scenario is triggered if support near $940 fails.

Viktoras Karapetjanc, expert at Traders Union, sees Eli Lilly maintaining its longer-term strength despite recent weakness. He notes that impressive earnings and strategic investments reflect solid fundamentals, even as short-term momentum remains weak. The expert believes the stock is consolidating near support with sellers still in control. However, sentiment could shift if the $1,036.27 resistance is reclaimed. "If current support holds, I expect Eli Lilly’s fundamental strength and improving macro backdrop to underpin a rebound in coming weeks."

Earlier, analysts noted that Eli Lilly was experiencing persistent selling pressure in the short and medium term while maintaining long-term technical support. The current article strengthens this outlook with fresh earnings data and ongoing supply chain investments, highlighting a period of sideways-to-bearish price action where a failure of support near $940 could accelerate downside risk.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.